NeuroVision Imaging Inc. has confirmed the acquisition of Durin Life Sciences Inc. in a move designed to create a unified platform for detecting and managing neurodegenerative diseases. The announcement was made on May 12, 2026, in Sacramento, California. This deal brings together blood-based biomarker testing with retinal imaging and digital health services to help identify brain health issues much earlier than before.
The new organisation will keep the NeuroVision name and will be managed by Steven Verdooner, the current CEO and co-founder. By merging these technologies, the company plans to speed up the rollout of diagnostic tools for conditions like Alzheimer’s disease, Parkinson’s disease, and ALS. The strategy relies on combining laboratory science with a nationwide telehealth system to monitor patients over long periods.
Durin Life Sciences is known for creating Duritect, which is a collection of blood tests meant for the early discovery of neurological disorders. NeuroVision provides the infrastructure through its BrainHealth.net platform. This digital service currently assists patients and doctors across the United States with cognitive tests and care plans. Ric Edelman, who was the majority owner of Durin, will now take a seat on the board of the merged company.
Steven Verdooner said: “We’ve long believed that the future of neurodegenerative disease care begins with earlier and more accessible detection. Durin’s blood-based biomarker platform represents an important advancement in that direction. By bringing together complementary strengths in diagnostics, technology and patient engagement, we believe we are uniquely positioned to help advance brain health at scale while supporting patients and families throughout the care journey.”
In response to the deal, Ric Edelman said: “This is a milestone for Durin and for everyone who has been part of our journey, and we’re excited to be joining forces with NeuroVision.”
The combined firm hopes to make brain health management more accessible by using scalable data and patient engagement tools. This merger marks a shift toward longitudinal care, where patients are monitored continuously rather than just at the point of crisis.
